Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2021 November;87(11) > Minerva Anestesiologica 2021 November;87(11):1209-16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   Freefree

Minerva Anestesiologica 2021 November;87(11):1209-16

DOI: 10.23736/S0375-9393.21.15595-6

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Comparison of renal replacement therapy and renal recovery before and during the COVID-19 pandemic: a single center observational study

Rebecca RYAN 1, Isabel TAYLOR 1, Chris LAING 2, Mervyn SINGER 1, 3, Dereck GONDONGWE 1, Niall MACCALLUM 1, Nishkantha ARULKUMARAN 1, 3

1 Intensive Care Unit, University College London Hospital, London, UK; 2 Department of Renal Medicine, University College London, Royal Free Hospital, London, UK; 3 Division of Medicine, Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK



BACKGROUND: Our objective was to the describe indications, management, complications and outcomes of renal replacement therapy (RRT) in COVID-19 critically ill patients. To contextualize these findings, comparisons were made against 36 non-COVID-19 consecutive patients requiring RRT on ICU.
METHODS: We conducted a retrospective single center observational cohort study of patients requiring acute RRT between 1st March and 30th June 2020. Comparison was made against those receiving RRT in the pre-COVID-19 period from January 2019 to February 2020.
RESULTS: Of 154 COVID-19 patients, 47 (30.5%) received continuous venovenous hemofiltration (CVVHF), all of whom required mechanical ventilation and vasopressor support. The requirement for RRT was related to fluid balance rather than azotemia. Compared to 36 non-COVID-19 patients, those with COVID-19 were younger (P=0.016) with a lower serum creatinine on hospital admission (P=0.049), and lesser degrees of metabolic acidosis (P<0.001) and lactatemia (P<0.001) before initiation of RRT. In addition, the duration of RRT requirement was longer (P<0.001). Despite lower CVVHF exchange rates with higher serum creatinine levels following RRT initiation in the COVID-19 patients, metabolic abnormalities were corrected. Hospital mortality was 60% among COVID-19 patients requiring RRT, compared to 67% in non-COVID-19 patients (P=0.508), and renal recovery among survivors without pre-existing CKD was similar (P=0.231).
CONCLUSIONS: The requirement for RRT in COVID-19 patients was primarily related to fluid balance. Using lower CVVHF exchange rates was effective to correct metabolic abnormalities. Renal recovery occurred in all but one patient by 60 days in the 40% of patients who survived.


KEY WORDS: Renal replacement therapy; COVID-19; Critical illness

top of page